Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.


Listen to the latest hemonc news from international experts

High-risk MDS: unmet needs and future treatment approaches

Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms, and the treatment and management of high-risk MDS remains a challenge. With only two agents currently approved by the FDA and available to patients with high-risk disease, several experts agree that novel therapeutic strategies should be explored. Many ongoing clinical trials are evaluating the safety and efficacy of combination therapies, with the aim of providing more hope for patients and overcoming challenges in the field.

In this exclusive podcast, you will hear from leading experts Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, and Justin Taylor, MD, Sylvester Comprehensive Cancer Center, Miami, FL, who discuss the current state of the art in high-risk MDS, unmet needs, and future therapeutic approaches.

Date: 19th August 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter